MedPath

An Open labeled study in efficacy of add-on Ayurveda intervention in comparison with standard in Covid-19 patients with moderate severity and with type 2 diabetes followed by 60 day follwo-up

Phase 2
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Registration Number
CTRI/2020/12/029985
Lead Sponsor
AVP Research Foundation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

(i) Confirmed case of COVID with RT-PCR method not requiring ventilator or Intensive Care Unit support at the time of induction (ii) Aged above 18 years and less than equal to 70 years willing to give informed consent. (iii) Patients with Diabetes Mellitus Type II as co-morbidity (v) Arterial SpO2 in Room air less than or equal to 95 % or more than or equal to 90% at baseline (vi) NLR more than or equal to 3 (vii) IL6 not less than 25 (viii) CT score not less than 25% and not more than 50% of Lung consolidation (CORAD Score equivalent to the same) (ix) Patients on both Remdisivir and steroids

Exclusion Criteria

Co-morbidities like acute and advanced stage of chronic obstructive pulmonary disease, malignancy, chronic liver diseases, recent history of cardiovascular events, renal diseases, HIV patients, Pregnant and Lactating women, acute inflammatory complications of diabetes like non-healing ulcers /severe neuropathy, Patient requiring ventilator support as decided by medical team, Type I Diabetes Mellitus, History of CVA or Stroke. Covid-19 induced hyperglycemia, any subject having any affiliation to the participating institutions will be excluded.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Improve the response of the patient through integrative therapy <br/ ><br>2. Changes in inflammatory markers IL6, CRP <br/ ><br>3. Modulation of NLR ratio. <br/ ><br>4. Long term effect of Integrative therapy on lung, cardiac, liver and renal functions and neuropsychological symptoms. <br/ ><br> <br/ ><br>Timepoint: Timeline <br/ ><br>Day 0 <br/ ><br>Day 7 <br/ ><br>Day 11 <br/ ><br>Day 14 <br/ ><br>Day 28 <br/ ><br>Day 60 <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
5.Changes in Hematological and Biochemical parameter like CBC, Liver function test, Renal function test, Prothrombin time, Ferritin, D-Dimer, TroponinTimepoint: Timeline <br/ ><br>Day 0 <br/ ><br>Day 7 <br/ ><br>Day 11 <br/ ><br>Day 14 <br/ ><br>Day 28 <br/ ><br>Day 60
© Copyright 2025. All Rights Reserved by MedPath